Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms

Bayer has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or caused by adjuvant endocrine therapy.

Recent survey showed that 67% of European women reported vasomotor symptoms during menopause transition.

from Breaking World Pharma News https://ift.tt/jCtXes7